Why Generic Drugs Affect People Differently: Bioequivalence, NTI Medications, and Real-World Risks
Explore why generic drugs affect individuals differently. Learn about bioequivalence limits, the impact of inactive ingredients, and risks for Narrow Therapeutic Index medications.
FDA Abbreviated New Drug Application (ANDA) Process Explained: How Generics Beat Brand Names
The FDA's Abbreviated New Drug Application (ANDA) process allows generic drugs to gain approval by proving equivalence to brand names, skipping costly clinical trials. This guide explains the Hatch-Waxman Act, bioequivalence requirements, and how ANDAs drive down healthcare costs.
Sustaining Health After Switching to Generics: A Long-Term Guide
Learn how to maintain long-term health when switching from brand-name to generic medications, including risks of bioequivalence and strategies for NTI drugs.
Quality by Design in Generic Drug Development: Modern Science-Based Approaches
Quality by Design (QbD) has transformed generic drug development by shifting from end-product testing to science-based process control. Learn how FDA-mandated QbD improves approval rates, cuts review times, and enables flexible manufacturing through design spaces and real-time monitoring.